"Quinolizines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
| Descriptor ID |
D011807
|
| MeSH Number(s) |
D03.633.100.834
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Quinolizines".
Below are MeSH descriptors whose meaning is more specific than "Quinolizines".
This graph shows the total number of publications written about "Quinolizines" by people in this website by year, and whether "Quinolizines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1997 | 3 | 0 | 3 |
| 2001 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Quinolizines" by people in Profiles.
-
Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine3 receptor antagonists. Ann Pharmacother. 2003 Sep; 37(9):1276-86.
-
Dorsal root ganglion neurons express multiple nicotinic acetylcholine receptor subtypes. J Neurophysiol. 2001 Oct; 86(4):1773-82.
-
Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy. J Clin Oncol. 1997 Aug; 15(8):2966-73.
-
Prevention of acute emesis in cancer patients following high-dose cisplatin with the combination of oral dolasetron and dexamethasone. J Clin Oncol. 1997 May; 15(5):2135-8.
-
The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Ann Oncol. 1997 Feb; 8(2):181-5.
-
Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group. J Clin Oncol. 1996 Aug; 14(8):2242-9.